Oncohematology Unit

The Oncohematology Unit is dedicated to translational research focused on adult acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). The primary objective of the Unit is to elucidate the molecular and cellular mechanisms underlying chemoresistance, with a particular emphasis on how leukemic cells detect, respond to, and repair DNA damage. By integrating advanced molecular biology techniques, functional genomics, and drug screening approaches, we aim to uncover new vulnerabilities in resistant leukemia cells. From a translational standpoint, our goal is to identify and develop innovative pharmacological strategies capable of overcoming resistance to conventional and targeted therapies. Our experimental approach exploits the use of 3D models, nanoparticles and innovative drug combinations to overcome chemoresistance in acute leukemia patients.

Coordinator

Postodoctoral Researcher

No results found.

Selected Pubblications

  1. Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. Ghelli Luserna di Rorà A, Jandoubi M, Padella A, Ferrari A, Marranci A, Mazzotti C, Olimpico F, Ghetti M, Ledda L, Bochicchio MT, Paganelli M, Zanoni M, Cafaro A, Servili C, Galimberti S, Gottardi M, Rondoni M, Endri M, Onofrillo D, Audisio E, Marconi G, Simonetti G, Martinelli G.  J Transl Med. 2024 Nov 26;22(1):1062. doi: 10.1186/s12967-024-05838-9. PMID: 39587643; PMCID: PMC11590640
  2. Exploring the ATR-CHK1 pathway in the response of Doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.  Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G. Cell Biol Toxicol 2022
  3. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. Simonetti G, Mengucci C, Padella A, Fonzi E, Picone G, Delpino C, Nanni J, De Tommaso R, Franchini E, Papayannidis C, Marconi G, Pazzaglia M, Perricone M, Scarpi E, Fontana MC, Bruno S, Tebaldi M, Ferrari A, Bochicchio MT, Ghelli Luserna Di Rorà A, Ghetti M, Napolitano R, Astolfi A, Baldazzi C, Guadagnuolo V, Ottaviani E, Iacobucci I, Cavo M, Castellani G, Haferlach T, Remondini D, Capozzi F, Martinelli G.. Leukemia. 2021
  4. Targeting WEE1 to enhance conventional therapies for Acute Lymphoblastic Leukemia. Ghelli Luserna Di Rorà A, Beeharry N, Imbrogno E, Ferrari A, Robustelli V, Righi S, Sabattini E, Verga Falzacappa MV, Ronchini C, Testoni N, Baldazzi C, Papayannidis C, Abbenante MC, Marconi G, Paolini S, Parisi S, Sartor C, Fontana MC, De Matteis S, Iacobucci I, Pelicci PG, Cavo M, Yen TJ, Martinelli G Journal of Hematology and Oncology, 2018
  5. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. Iacobucci I*, Ghelli Luserna di Rora’ A*, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G. *co-first authors, Journal of Hematology and Oncology, 2015